InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
2
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-12.1%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Howell Peyton R. Director active across 2 companies, notably TANDEM DIABETES CARE INC. Aggregated, 10 disclosures have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €91k. Activity tracked since 3 August 2021. The latest transaction was filed on 22 May 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations10 total
4,387 shares@ US$20.6421.0% of flowCommon StockSEC:0001438133-25-000105:0
4,434 shares@ US$51.7355.4% of flowCommon StockSEC:0001438133-24-000126:0
949 shares0Common StockSEC:0001438133-23-000157:0
2,757 shares0Common StockSEC:0001438133-23-000106:0
3,000 shares@ US$30.16421.8% of flowCommon StockSEC:0001438133-23-000090:0
Ideal exit: 11 Feb 2024 (T+270)
949 shares0Common StockSEC:0001438133-22-000183:0
1,653 shares0Common StockSEC:0001438133-22-000097:0
100 shares@ US$75.20970.0005% mcap100.0% of flowCommon StockSEC:0001438133-22-000067:0
Ideal exit: 31 Jan 2023 (T+270)
948 shares0Common StockSEC:0001438133-21-000123:0
948 shares0Common StockSEC:0001438133-21-000123
10 of 10 declarations
About Howell Peyton R
Howell Peyton R is a declarant linked to Tandem Diabetes Care INC and TANDEM DIABETES CARE INC, where he is a Director. The record shows 10 filings in total, and among the recent filings covered, the cumulative purchases amount to EUR 90628, with no sales, between 2021-08-05 and 2025-05-23; the most common transaction nature is Option exercise.
